Cyclovirobuxine D

Catalog No.S2402 Batch:S240202

Print

Technical Data

Formula

C26H46N2O
Molecular Weight 402.66 CAS No. 860-79-7
Solubility (25°C)* In vitro Ethanol 7 mg/mL (17.38 mM)
DMSO Insoluble
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%ethyl alcohol 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 1mg/ml (2.48mM) Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified ethyl alcohol stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution
5% ethyl alcohol 95% Corn oil

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 1mg/ml (2.48mM) Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clear ethyl alcohol stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Cyclovirobuxine D (Cyclovirobuxin D, Cyclovirobuxine, Bebuxine, CVB-D) is an active compound extracted from Buxus microphylla, which has been used for treating acute myocardial ischemia.
In vitro Cyclovirobuxine D increases cardiomyocytes viability injured by oxidation or hypoxia. It significantly reduces the infarct size induced by ligating the coronary artery in rats. In addition, Cyclovirobuxine D protects rat aorta endothelial cells against hypoxia and enhanced nitric oxide (NO) release from endothelial cells. [1] Cyclovirobuxine D facilitates the utilization of intracellular Ca(2+) and prevents the loss of Ca(2+), which may be the underlying mechanism of its protective effect on heart failure. [4]
In vivo Cyclovirobuxine D decreases the weight of venous thrombus in rats. [1] Cyclovirobuxine D causes a primary effect of coronary vasodilatation in anesthetized pigs, which involves mechanisms related to the endothelial release of nitric oxide. [2] In addition, Cyclovirobuxine D is beneficial for heart failure in rats induced by myocardial infarction. [3] LD50: Mice 8.9mg/kg (i.v.), 9.2mg/kg (i.p.), 293mg/kg (i.g.). [5]

Protocol (from reference)

References

  • http://www.ncbi.nlm.nih.gov/pubmed/17555743
  • http://www.ncbi.nlm.nih.gov/pubmed/10462084
  • http://www.ncbi.nlm.nih.gov/pubmed/21575690
  • http://www.ncbi.nlm.nih.gov/pubmed/23022536

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.